vorinostat has been researched along with Leukemia in 37 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 9.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
| " Suberoylanilidehydroxamic acid (SAHA=vorinostat) is the most clinical advanced compound of the class and was approved by the US FDA in October 2006 for the treatment of refractory cutaneous T-cell lymphoma." | 9.16 | Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. ( Abel, U; Deubzer, HE; Eisenmenger, A; Karapanagiotou-Schenkel, I; Kulozik, A; Milde, T; Oehme, I; Witt, O; Witt, R, 2012) |
| "Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia." | 9.13 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. ( Bueso-Ramos, C; Chen, C; Cortes, J; Faderl, S; Fantin, VR; Ferrajoli, A; Frankel, SR; Garcia-Manero, G; Hardwick, JS; Kantarjian, HM; Koller, C; Loboda, A; Morris, G; Randolph, SS; Reilly, JF; Richon, VM; Ricker, JL; Rosner, G; Secrist, JP; Wierda, WG; Yang, H, 2008) |
| " The aim of the present study was to investigate the effect of combination treatment with PARP inhibitor PJ34 and HDAC inhibitor vorinostat on human leukemia cell lines." | 7.80 | Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines. ( Gajda, M; Jasek, E; Jasińska, M; Lis, GJ; Litwin, JA, 2014) |
| "Interactions between the novel Chk1 inhibitor MK-8776 and the histone deacetylase (HDAC) inhibitor (HDACI) vorinostat were examined in human leukemia cells harboring wild-type (wt) or deficient p53." | 7.79 | The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. ( Chen, S; Dai, Y; Grant, S; Kmieciak, M; Lin, H; Pei, XY; Zhou, L, 2013) |
| "Interactions between histone deacetylase inhibitors (HDACIs) and the alkyl-lysophospholipid perifosine were examined in human leukemia cells." | 7.73 | Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. ( Bauer, C; Dai, Y; Dent, P; Grant, S; Payne, SG; Rahmani, M; Reese, E; Spiegel, S, 2005) |
| "This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 5.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
| " Suberoylanilidehydroxamic acid (SAHA=vorinostat) is the most clinical advanced compound of the class and was approved by the US FDA in October 2006 for the treatment of refractory cutaneous T-cell lymphoma." | 5.16 | Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. ( Abel, U; Deubzer, HE; Eisenmenger, A; Karapanagiotou-Schenkel, I; Kulozik, A; Milde, T; Oehme, I; Witt, O; Witt, R, 2012) |
| "Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia." | 5.13 | Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. ( Bueso-Ramos, C; Chen, C; Cortes, J; Faderl, S; Fantin, VR; Ferrajoli, A; Frankel, SR; Garcia-Manero, G; Hardwick, JS; Kantarjian, HM; Koller, C; Loboda, A; Morris, G; Randolph, SS; Reilly, JF; Richon, VM; Ricker, JL; Rosner, G; Secrist, JP; Wierda, WG; Yang, H, 2008) |
| " The aim of the present study was to investigate the effect of combination treatment with PARP inhibitor PJ34 and HDAC inhibitor vorinostat on human leukemia cell lines." | 3.80 | Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines. ( Gajda, M; Jasek, E; Jasińska, M; Lis, GJ; Litwin, JA, 2014) |
| "Interactions between the novel Chk1 inhibitor MK-8776 and the histone deacetylase (HDAC) inhibitor (HDACI) vorinostat were examined in human leukemia cells harboring wild-type (wt) or deficient p53." | 3.79 | The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. ( Chen, S; Dai, Y; Grant, S; Kmieciak, M; Lin, H; Pei, XY; Zhou, L, 2013) |
| " We found that 4 histone deacetylase inhibitors, trichostatin A (TSA), sodium butyrate (SB), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), all significantly induced EBV lytic cycle in EBV-positive gastric carcinoma cells (AGS/BX1, latency II) but only weakly induced in Burkitt lymphoma cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III)." | 3.76 | Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. ( Chiang, AK; Hui, KF, 2010) |
| "We analyzed the cellular and molecular effects of two different HDACi (MGCD0103 and vorinostat) in combination with GX15-070 in leukemia cell lines and primary acute myelogenous leukemia cells." | 3.76 | The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. ( Garcia-Manero, G; Hu, Y; Jia, Y; Kadia, T; O'Brien, S; Tambaro, FP; Tong, W; Viallet, J; Wei, Y; Yang, H; Zhang, M, 2010) |
| " A gene expression analysis performed in a phase 1 trial of vorinostat in leukemia indicated that overexpression of genes involved in antioxidant defense was associated with clinical resistance." | 3.76 | Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. ( Bhalla, K; Chen, G; Fiskus, W; Garcia-Manero, G; Hu, Y; Huang, P; Jia, Y; Keating, M; Lu, W; Wei, Y; Yang, H; Zhang, H; Zhang, W, 2010) |
| "Interactions between histone deacetylase inhibitors (HDACIs) and the alkyl-lysophospholipid perifosine were examined in human leukemia cells." | 3.73 | Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. ( Bauer, C; Dai, Y; Dent, P; Grant, S; Payne, SG; Rahmani, M; Reese, E; Spiegel, S, 2005) |
| " HDACi have single-agent clinical activity in haematological malignancies and have synergistic anti-leukaemia activity when combined with anthracyclines in vitro." | 2.75 | A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. ( Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.70) | 18.2507 |
| 2000's | 10 (27.03) | 29.6817 |
| 2010's | 20 (54.05) | 24.3611 |
| 2020's | 6 (16.22) | 2.80 |
| Authors | Studies |
|---|---|
| Salmi-Smail, C | 1 |
| Fabre, A | 1 |
| Dequiedt, F | 1 |
| Restouin, A | 1 |
| Castellano, R | 1 |
| Garbit, S | 1 |
| Roche, P | 1 |
| Morelli, X | 1 |
| Brunel, JM | 1 |
| Collette, Y | 1 |
| Li, X | 3 |
| Zhang, Y | 2 |
| Jiang, Y | 1 |
| Wu, J | 1 |
| Inks, ES | 2 |
| Chou, CJ | 2 |
| Gao, S | 1 |
| Hou, J | 1 |
| Ding, Q | 1 |
| Li, J | 2 |
| Wang, X | 1 |
| Huang, Y | 2 |
| Xu, W | 1 |
| Peterson, YK | 1 |
| Himes, RA | 1 |
| Kong, X | 1 |
| Gu, X | 1 |
| Guan, M | 1 |
| Jiang, C | 1 |
| Song, Q | 1 |
| Sun, N | 1 |
| Zou, Y | 1 |
| Zhou, Q | 1 |
| Chen, J | 1 |
| Qiu, J | 1 |
| Alves Avelar, LA | 1 |
| Schrenk, C | 1 |
| Sönnichsen, M | 1 |
| Hamacher, A | 1 |
| Hansen, FK | 2 |
| Schliehe-Diecks, J | 2 |
| Borkhardt, A | 2 |
| Bhatia, S | 2 |
| Kassack, MU | 1 |
| Kurz, T | 1 |
| Schäker-Hübner, L | 1 |
| Warstat, R | 1 |
| Ahlert, H | 1 |
| Mishra, P | 1 |
| Kraft, FB | 1 |
| Schöler, A | 1 |
| Breit, B | 1 |
| Hügle, M | 1 |
| Günther, S | 1 |
| Wu, S | 1 |
| Wang, T | 1 |
| Li, K | 1 |
| Lu, J | 1 |
| Huang, M | 1 |
| Dong, G | 1 |
| Sheng, C | 1 |
| Wang, ZX | 1 |
| Wang, S | 1 |
| Qiao, XP | 1 |
| Li, WB | 1 |
| Shi, JT | 1 |
| Wang, YR | 1 |
| Chen, SW | 1 |
| Mansour, RE | 1 |
| Abdulwahab, HG | 1 |
| El-Sehrawi, HM | 1 |
| Holkova, B | 1 |
| Supko, JG | 1 |
| Ames, MM | 1 |
| Reid, JM | 1 |
| Shapiro, GI | 1 |
| Perkins, EB | 1 |
| Ramakrishnan, V | 1 |
| Tombes, MB | 1 |
| Honeycutt, C | 1 |
| McGovern, RM | 1 |
| Kmieciak, M | 2 |
| Shrader, E | 1 |
| Wellons, MD | 1 |
| Sankala, H | 1 |
| Doyle, A | 1 |
| Wright, J | 1 |
| Roberts, JD | 1 |
| Grant, S | 7 |
| Dai, Y | 4 |
| Chen, S | 1 |
| Zhou, L | 1 |
| Lin, H | 1 |
| Pei, XY | 1 |
| Brodská, B | 3 |
| Holoubek, A | 1 |
| Otevřelová, P | 3 |
| Kuželová, K | 3 |
| Jasek, E | 1 |
| Gajda, M | 1 |
| Lis, GJ | 1 |
| Jasińska, M | 1 |
| Litwin, JA | 1 |
| Park, S | 1 |
| Park, JA | 1 |
| Kim, YE | 1 |
| Song, S | 1 |
| Kwon, HJ | 1 |
| Lee, Y | 1 |
| Hülsdünker, J | 1 |
| Zeiser, R | 1 |
| Chao, MW | 1 |
| Lai, MJ | 1 |
| Liou, JP | 1 |
| Chang, YL | 1 |
| Wang, JC | 1 |
| Pan, SL | 1 |
| Teng, CM | 1 |
| Lee, JS | 1 |
| Jeong, SH | 1 |
| Soung, YH | 1 |
| Kim, TH | 1 |
| Choi, HJ | 1 |
| Park, BS | 1 |
| Kwon, TK | 1 |
| Yoo, YH | 1 |
| Hui, KF | 1 |
| Chiang, AK | 1 |
| Pluskalová, M | 2 |
| Elknerová, K | 1 |
| Grebenová, D | 2 |
| Hrkal, Z | 1 |
| Kadia, TM | 1 |
| Yang, H | 5 |
| Ferrajoli, A | 2 |
| Maddipotti, S | 1 |
| Schroeder, C | 1 |
| Madden, TL | 1 |
| Holleran, JL | 1 |
| Egorin, MJ | 1 |
| Ravandi, F | 1 |
| Thomas, DA | 1 |
| Newsome, W | 1 |
| Sanchez-Gonzalez, B | 2 |
| Zwiebel, JA | 1 |
| Espinoza-Delgado, I | 1 |
| Kantarjian, HM | 2 |
| Garcia-Manero, G | 5 |
| Wei, Y | 2 |
| Kadia, T | 1 |
| Tong, W | 1 |
| Zhang, M | 1 |
| Jia, Y | 2 |
| Hu, Y | 2 |
| Tambaro, FP | 1 |
| Viallet, J | 1 |
| O'Brien, S | 1 |
| Lu, W | 1 |
| Chen, G | 1 |
| Zhang, H | 1 |
| Zhang, W | 1 |
| Fiskus, W | 1 |
| Bhalla, K | 1 |
| Keating, M | 1 |
| Huang, P | 1 |
| Aldabagh, B | 1 |
| Patel, RR | 1 |
| Honda, K | 1 |
| Muscal, JA | 1 |
| Scorsone, KA | 1 |
| Zhang, L | 1 |
| Ecsedy, JA | 1 |
| Berg, SL | 1 |
| Maxmen, A | 1 |
| Witt, O | 1 |
| Milde, T | 1 |
| Deubzer, HE | 1 |
| Oehme, I | 1 |
| Witt, R | 1 |
| Kulozik, A | 1 |
| Eisenmenger, A | 1 |
| Abel, U | 1 |
| Karapanagiotou-Schenkel, I | 1 |
| Röselová, P | 1 |
| Halada, P | 1 |
| Rösel, D | 1 |
| Suttnar, J | 1 |
| Reddy, P | 1 |
| Maeda, Y | 1 |
| Hotary, K | 1 |
| Liu, C | 1 |
| Reznikov, LL | 1 |
| Dinarello, CA | 1 |
| Ferrara, JL | 1 |
| Gao, N | 1 |
| Rahmani, M | 3 |
| Dent, P | 3 |
| Sakajiri, S | 1 |
| Kumagai, T | 1 |
| Kawamata, N | 1 |
| Saitoh, T | 1 |
| Said, JW | 1 |
| Koeffler, HP | 1 |
| Reese, E | 1 |
| Bauer, C | 1 |
| Payne, SG | 1 |
| Spiegel, S | 1 |
| Bueso-Ramos, C | 2 |
| Hoshino, K | 1 |
| Quintas-Cardama, A | 1 |
| Richon, VM | 3 |
| Castro-Galache, MD | 1 |
| Menéndez-Gutiérrez, MP | 1 |
| Carrasco Garcia, E | 1 |
| Garcia-Morales, P | 1 |
| Martinez-Lacaci, I | 1 |
| Saceda, M | 1 |
| Ferragut, JA | 1 |
| Cortes, J | 1 |
| Wierda, WG | 1 |
| Faderl, S | 1 |
| Koller, C | 1 |
| Morris, G | 1 |
| Rosner, G | 1 |
| Loboda, A | 1 |
| Fantin, VR | 1 |
| Randolph, SS | 1 |
| Hardwick, JS | 1 |
| Reilly, JF | 1 |
| Chen, C | 1 |
| Ricker, JL | 1 |
| Secrist, JP | 1 |
| Frankel, SR | 1 |
| Vrana, JA | 1 |
| Decker, RH | 1 |
| Johnson, CR | 1 |
| Wang, Z | 1 |
| Jarvis, WD | 1 |
| Ehinger, M | 1 |
| Fisher, PB | 1 |
| Almenara, J | 1 |
| Rosato, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children With Relapsed Solid Tumor, Lymphoma or Leukemia[NCT01422499] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Phase II Clinical Evaluation of Vorinostat Combined With Salvage Reinduction Chemotherapy Including Gemtuzumab Ozogamicin, Idarubicin and Cytarabine and Vorinostat Maintenance in Relapse or Refractory Acute Myeloid Leukemia Patients With 50 Years or Older[NCT01039363] | Phase 2 | 27 participants (Anticipated) | Interventional | Not yet recruiting | |||
| Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy[NCT01617226] | Phase 2 | 260 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for vorinostat and Leukemia
| Article | Year |
|---|---|
Insights into the pathogenesis of GvHD: what mice can teach us about man.
Topics: Adoptive Transfer; Animals; Antineoplastic Agents; Disease Models, Animal; Graft vs Host Disease; Gr | 2015 |
4 trials available for vorinostat and Leukemia
| Article | Year |
|---|---|
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemo | 2013 |
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Topics: Acetylation; Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combi | 2010 |
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Rela | 2012 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase I as Topic; Dose-Res | 2008 |
32 other studies available for vorinostat and Leukemia
| Article | Year |
|---|---|
Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Cell Line, Tumor; Drug Screening Assays, Antitumor | 2010 |
Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Colon; Colorectal Neoplasms; HCT116 | 2017 |
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; CD13 Antigens; Cell Cycle Checkpoints; Cell Line, Tumor | 2018 |
Discovery of thiosemicarbazone-containing compounds with potent anti-proliferation activity against drug-resistant K562/A02 cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Prol | 2020 |
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Drug Synergism; Epigenomics; Head and Neck Neoplasms; Histone Deac | 2021 |
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Anti | 2021 |
Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening | 2022 |
Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Ant | 2022 |
Novel benzimidazole-linked (thio)barbiturates as non-hydroxamate HDAC6 inhibitors targeting leukemia: Design, synthesis, and structure-activity relationship.
Topics: Antineoplastic Agents; Barbiturates; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Desi | 2023 |
The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Cells, Cultured; Check | 2013 |
Combined treatment with low concentrations of decitabine and SAHA causes cell death in leukemic cell lines but not in normal peripheral blood lymphocytes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitid | 2013 |
Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; D | 2014 |
Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.
Topics: Acetylcysteine; Amino Acid Chloromethyl Ketones; Caspase 10; Caspase Inhibitors; Caspases; fas Recep | 2015 |
The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Hydroxam | 2015 |
SAHA treatment overcomes the anti-apoptotic effects of Bcl-2 and is associated with the formation of mature PML nuclear bodies in human leukemic U937 cells.
Topics: Apoptosis; Blotting, Western; Caspase 3; Electrophoresis, Polyacrylamide Gel; Fluorescent Antibody T | 2009 |
Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Butyrates; Carcinoma; Cell Cy | 2010 |
Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Separatio | 2010 |
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Cell Line, Tumor; | 2010 |
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
Topics: Antioxidants; Base Sequence; Cell Line, Tumor; Cell Survival; DNA Primers; Drug Resistance, Neoplasm | 2010 |
Leukemia cutis in association With Grover's disease.
Topics: Acantholysis; Aged; Antineoplastic Agents; Biopsy; Dermis; Fatal Outcome; Flavonoids; Humans; Hydrox | 2011 |
Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Azepines; Cell Line, Tumor; Cell Survival; D | 2013 |
Cancer research: Open ambition.
Topics: Adult; Animals; Azepines; Benzodiazepines; Cell Cycle Proteins; Child; Epigenesis, Genetic; Histone | 2012 |
Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells.
Topics: Acetylation; Antineoplastic Agents; Cell Adhesion; HL-60 Cells; Humans; Hydroxamic Acids; K562 Cells | 2012 |
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Topics: Animals; Bone Marrow Transplantation; Cytokines; Female; Graft vs Host Disease; Histone Deacetylase | 2004 |
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Topics: Antineoplastic Agents; Apoptosis; Butyrates; Caspases; Cyclin-Dependent Kinase Inhibitor p21; Cyclin | 2004 |
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation | 2005 |
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Butyrates; Ce | 2005 |
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Topics: Acetylation; Apoptosis; Benzamides; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Gene Expr | 2005 |
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2006 |
Protein kinase C-alpha antagonizes apoptosis induction by histone deacetylase inhibitors in multidrug resistant leukaemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enz | 2007 |
Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.
Topics: Apoptosis; bcl-X Protein; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Down-Regulation; Humans; H | 1999 |
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Topics: Antineoplastic Agents; Apoptosis; Caspase 8; Caspase 9; Caspases; Cyclin-Dependent Kinases; Drug Syn | 2002 |